Evidence map›Paper›PMID 34737569›Full record

ArticleNeuropsychiatric disease and treatment2021

Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records.

Sheryl Ker, Jennifer Hsu, Anisha Balani, Sankha Subhra Mukherjee, A John Rush, Mehreen Khan, Sara Elchehabi, Seth Huffhines, Dustin DeMoss, Miguel E Rentería and 1 more

Open access · goldAbstract read
In one paragraph

Article in Neuropsychiatric disease and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Sheryl Ker *Holmusk Technologies, Inc., New York, NY, USA.ORCID 0000-0002-0732-1216
Jennifer Hsu *John Peter Smith Health Network, Fort Worth, TX, USA.
Anisha Balani *Holmusk Technologies, Inc., New York, NY, USA.
Sankha Subhra MukherjeeHolmusk Technologies, Inc., New York, NY, USA.ORCID 0000-0001-8964-7537
A John RushDepartment of Psychiatry, Duke-National University of Singapore (NUS), Singapore.ORCID 0000-0003-2004-2382
Mehreen KhanJohn Peter Smith Health Network, Fort Worth, TX, USA.
Sara ElchehabiJohn Peter Smith Health Network, Fort Worth, TX, USA.
Seth HuffhinesJohn Peter Smith Health Network, Fort Worth, TX, USA.
Dustin DeMossJohn Peter Smith Health Network, Fort Worth, TX, USA.
Miguel E RenteríaHolmusk Technologies, Inc., New York, NY, USA.ORCID 0000-0003-4626-7248
Joydeep SarkarHolmusk Technologies, Inc., New York, NY, USA.
John Peter Smith Hospital · USNational University of Singapore · SGUniversity of North Texas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe attrition patterns of opioid use disorder (OUD) patients treated with buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication dosing features are associated with attrition. PATIENTS AND

methodsElectronic health records of adults (16+ year-olds) with OUD treated with BUP from 23 different substance use or mental health care programs across 11 US states were examined for one year following BUP initiation in inpatient (IP), intensive outpatient (IOP), or outpatient (OP) settings. Treatment attrition was declared at >37 days following the last recorded visit. Survival analyses and predictive modelling were used.

resultsRetention was consistently 2-3 times higher following BUP initiation in OP (n = 2409) than in IP/IOP (n = 2749) settings after 2 (50% vs 25%), 6 (27% vs 9%) and 12 months (14% vs 4%). Retention was higher for females, whites (vs blacks), and those with less severe OUD, better global function, or not using non-psychotropic medications. Comorbid substance use, other psychiatric disorders, and the number of psychotropic medications were variously related to retention depending on the setting in which BUP was initiated. Predictive modelling revealed that a higher global assessment of functioning and a smaller OUD severity based on the Clinical Global Impression - Severity led to longer retentions, a higher initial BUP dose led to higher retention in a few cases, an OP setting of BUP initiation led to longer retentions, and a lower total number of psychotropic and non-psychotropic medications led to longer retentions. These were the most important parameters in the model, which identified 75.2% of patients who left BUP treatment within three months post-initiation, with a precision of 90.5%.

conclusionOf all the OUD patients who began BUP, 50-75% left treatment within three months, and most could be accurately identified. This could facilitate patient-centered management to better retain OUD patients in BUP treatment.

Indexed as

buprenorphinebuprenorphine dosingopioidspredictorstreatment dropouttreatment engagementtreatment retention

Identifiers

PMID34737569
PMCPMC8560173
OpenAlexW3209034575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.